CORNEAT EVERPATCH | SYNTHETIC SCLERA

First synthetic and non-degradable tissue substitute

CorNeat EverPatch

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. The CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.

The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the Extra Cellular Matrix (ECM) stimulating cellular colonization and integration with the surrounding tissue.

Indications

- Covering irritating implants such as in glaucoma tube shunts or exposed sutures, displacing the need for preserved tissue/collagen
- Covering tissue gaps/weaknesses, resulting either from traumatic, disease related or iatrogenic damage

CorNeat EverPatch Advantages

Everlasting
- Inert & non-degradable material
- Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response direct visualization while enabling future procedures in a similar fashion

Cost-Effective
- Reduces operating time and eye bank costs
- Eliminates complexities related to the transportation and storage of biological materials
- Readily available, off-the-shelf, device

Ease of Handling
- Extremely easy to handle and suture
- Elastic and durable (cannot be torn by the sutures)

Aesthetic
- Translucent when wet
- Hardly visible when implanted subconjunctivally

Safe
- Synthetic and therefore cannot carry or transmit disease

Development Phase

The first-in-human (FIH) clinical trial for the CorNeat EverPatch took place in December 2020. The surgery was conducted by Dr. Ike Ahmed at the Prism Eye Institute in Toronto, Canada. Clinical trials are also taking place in Kenya and France. The trials are geared toward obtaining a CE mark during 2022.

CorNeat Vision plans to extend the solution to the US market as a second step and work toward FDA approval. The exact FDA path will be coordinated with authorities during 2021 and expected to begin during 2022.

The plans above are subject to regulatory approvals and requirements.



corneat VISION

Biomimetic Implants and Technology | www.corneat.com | info@corneat.com